Etira Announces Update on ERX-315 Clinical Trial
Etira, a clinical-stage biopharmaceutical company developing groundbreaking cancer therapies, announced today that a patient has been successfully treated at Dose Level Three of ERX-315 in its ongoing Phase 1 trial. ERX-315 is a first-in-class small molecule drug designed to trigger endoplasmic reticulum stress, leading to cancer cell death across multiple tumor types. “The administration of ERX-315 at DL3 aligns with the therapeutically effective dose observed in our preclinical studies,” said Russell Hayward, Chief Executive Officer of Etira. 
Etira Announces Update on ERX-315 Clinical Trial